发明名称 |
MIG6 AND THERAPEUTIC EFFICACY |
摘要 |
We identify markers capable of guiding the decision to incorporate epidermal growth factor receptor (EGFR) inhibitors, in particular EGFR tyrosine kinase inhibitors (TKIs), into chemotherapeutic regimens. Mitogen-inducible gene 6 (Mig6), a negative regulator of EGFR, is selectively upregulated during the development of resistance to the EGFR tyrosine kinase inhibitor (TKI) erlotinib, resulting in decreased EGFR phosporylation. The ratio of Mig6/EGFR expression highly correlates with erlotinib sensitivity. A low Mig6/EGFR ratio correlates with a high response rate to gefitinib and a marked increase in progression-free survival for patients. The ratio of Mig6 to EGFR is a major predictor of biologic and clinical responses to EGFR inhibitors. |
申请公布号 |
WO2012018609(A3) |
申请公布日期 |
2012.05.31 |
申请号 |
WO2011US45331 |
申请日期 |
2011.07.26 |
申请人 |
THE JOHNS HOPKINS UNIVERSITY;SIDRANSKY, DAVID;CHANG, XIAOFEI |
发明人 |
SIDRANSKY, DAVID;CHANG, XIAOFEI |
分类号 |
G01N33/68;C12Q1/68;G01N33/574 |
主分类号 |
G01N33/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|